Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 at JPMorgan Chase & Co.

Replimune Group (NASDAQ:REPL) had its price objective upped by JPMorgan Chase & Co. from $16.00 to $18.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms have also recently issued reports on REPL. HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Stock Performance

NASDAQ:REPL opened at $13.24 on Wednesday. The company has a fifty day simple moving average of $12.74 and a two-hundred day simple moving average of $11.95. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -4.31 and a beta of 1.30. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC lifted its position in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after acquiring an additional 1,655 shares during the last quarter. Graham Capital Management L.P. lifted its position in Replimune Group by 6.1% in the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock valued at $365,000 after acquiring an additional 1,731 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock valued at $456,000 after buying an additional 2,525 shares during the last quarter. Algert Global LLC raised its holdings in shares of Replimune Group by 7.1% in the fourth quarter. Algert Global LLC now owns 45,820 shares of the company’s stock valued at $555,000 after buying an additional 3,057 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after buying an additional 3,177 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.